Dr Schoenberg will assist the company in its current effort to complete critical clinical trials with the Sonablate 500 technology in the treatment of patients with prostate cancer.
Additionally, Dr Schoenberg will spearhead a scholarly effort to critically evaluate current clinical experiences with high intensity focused ultrasound (HIFU) therapy in collaboration with the Sonablate International HIFU Registry.
Dr Schoenberg will also help USHIFU create educational materials describing the use of HIFU technology and will assist in developing a series of initiatives for the treatment of other malignancies.
Steve Puckett, Jr, CEO of USHIFU, said: “We are thrilled to announce the addition of Dr Mark Schoenberg to the USHIFU team as chief medical officer of our company. We look forward to leveraging Dr Schoenberg’s skill set as we continue to build a world class healthcare organization.”